Trial · NCT03440372
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percent of Participants With a Crohn's Disease Activity Index (CDAI) Score < 150 at Week 12 | At Week 12 | Intent to treat population consist of all randomized participants that received at least 1 dose of investigational drug | Percentage of Participants | NUMBER |
| SECONDARY | Percent of Participants With Average Daily Abdominal Pain Score ≤ 1 Point, and Average Daily Stool Frequency Score ≤ 3 Points With Abdominal Pain and Stool Frequency no Worse Than Baseline at Week 12 | At Week 12 | Intent to treat population consist of all randomized participants that received at least 1 dose of investigational drug | Percentage of Participants | NUMBER |
| SECONDARY | Percent of Participants With a Simple Endoscopic Score for Crohn's Disease (SES-CD) Score Decrease From Baseline of ≥ 50% at Week 12 | At Week 12 | Intent to treat population consist of all randomized participants that received at least 1 dose of investigational drug | Percentage of Participants | NUMBER |
| SECONDARY | Percent of Participants With Crohn's Disease Activity Index (CDAI) Reduction From Baseline of ≥ 100 Points or CDAI Score < 150 at Week 12 | At Week 12 | Intent to treat population consist of all randomized participants that received at least 1 dose of investigational drug | Percentage of Participants | NUMBER |
| SECONDARY | Percent of Participants With Crohn's Disease Activity Index (CDAI) Reduction From Baseline of ≥ 100 Points or CDAI Score < 150 and Simple Endoscopic Score for Crohn's Disease (SES-CD) Decrease From Baseline of ≥ 50% at Week 12 | At Week 12 | Intent to treat population consist of all randomized participants that received at least 1 dose of investigational drug | Percentage of Participants | NUMBER |
| SECONDARY | Percent of Participants With Crohn's Disease Activity Index (CDAI) Score < 150 at Week 12 and Simple Endoscopic Score for Crohn's Disease (SES-CD) Decrease From Baseline of ≥ 50% at Week 12 | At Week 12 | Intent to treat population consist of all randomized participants that received at least 1 dose of investigational drug | Percent of Participants | NUMBER |
| SECONDARY | Percent of Participants With an Average Daily Abdominal Pain Score ≤ 1 Point, and Average Daily Stool Frequency Score ≤ 3 Points With Abdominal Pain and Stool Frequency no Worse Than Baseline and an SES-CD ≤ 4 Points and Decrease ≥ 2 Points at Week 12 | At Week 12 | Intent to treat population consist of all randomized participants that received at least 1 dose of investigational drug | Percentage of Participants | NUMBER |
| SECONDARY | Percent of Participants With an Average Daily Abdominal Pain Score ≤ 1 Point, and Average Daily Stool Frequency Score ≤ 3 Points With Abdominal Pain and Stool Frequency Score no Worse Than Baseline and an SES-CD Decrease From Baseline of ≥ 50% at Week 12 | At Week 12 | Intent to treat population consist of all randomized participants that received at least 1 dose of investigational drug | Percentage of Participants | NUMBER |
| SECONDARY | Histologic Improvement Based on Differences Between Ozanimod and Placebo in Histologic Disease Activity Scores (ie, Global Histologic Activity Score (GHAS) Changes) at Week 12 | At Week 12 | Intent to treat population consist of all randomized participants that received at least 1 dose of investigational drug | Percentage of Participants | NUMBER |
| SECONDARY | Percent of Participants With Crohn's Disease Activity Index (CDAI) Reduction From Baseline of ≥ 70 Points at Week 12 | At Week 12 | Intent to treat population consist of all randomized participants that received at least 1 dose of investigational drug | Percentage of Participants | NUMBER |
| SECONDARY | Percent of Participants With Absence of Ulcers ≥ 0.5 cm With No Segment With Any Ulcerated Surface ≥ 10% at Week 12 | At Week 12 | Intent to treat population consist of all randomized participants that received at least 1 dose of investigational drug | Percentage of Participants | NUMBER |
| SECONDARY | Percent of Participants With a Crohn's Disease Endoscopic Index of Severity (CDEIS) Decrease From Baseline of ≥ 50% at Week 12 | At Week 12 | Intent to treat population consist of all randomized participants that received at least 1 dose of investigational drug | Percentage of Participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03440372/outcomes